Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Pipeline Review, H2 2016’, provides in depth analysis on Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Actelion Ltd

C4X Discovery Holdings PLC

Eisai Co., Ltd.

Hager Biosciences, LLC

Heptares Therapeutics Limited

Merck & Co., Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Overview 7

Therapeutics Development 8

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Stage of Development 8

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Therapy Area 9

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Indication 10

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Companies 13

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development 19

Actelion Ltd 19

C4X Discovery Holdings PLC 20

Eisai Co., Ltd. 21

Hager Biosciences, LLC 22

Heptares Therapeutics Limited 23

Merck & Co., Inc. 24

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles 25

DORA-12 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

EORA-101 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

HTL-6641 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

lemborexant - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecule to Antagonize Orexin Receptor Type 1 for Neurology - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

suvorexant - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Projects 39

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products 40

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Featured News & Press Releases 41

Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia 41

May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development 42

Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 43

Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 43

Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 45

Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 45

Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 47

May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 48

May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 48

Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 49

Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 49

Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 50

Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 50

Jun 13, 2012: Merck Announces New Positive Data From Two Pivotal Phase III Efficacy Trials Of Suvorexant For Treatment Of Insomnia 52

Feb 06, 2012: Merck Provides Update On Development Program For Investigational Insomnia Drug, Suvorexant 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Actelion Ltd, H2 2016 19

Pipeline by C4X Discovery Holdings PLC, H2 2016 20

Pipeline by Eisai Co., Ltd., H2 2016 21

Pipeline by Hager Biosciences, LLC, H2 2016 22

Pipeline by Heptares Therapeutics Limited, H2 2016 23

Pipeline by Merck & Co., Inc., H2 2016 24

Dormant Projects, H2 2016 39

Discontinued Products, H2 2016 40

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared